May 31, 2017 / 7:13 AM / 6 months ago

BRIEF-Novartis says BAF312 filing planned for H1 2018 in relapsing MS

May 31 (Reuters) - Novartis Ag

* Says 2017 u.s. Launch of ms drug glatopa 40 mg still possible, but unlikely after facility problems

* Says on track to launch five major biosimilars between now and 2020

* Says has 40 potential filings in us and eu 2017-2020

* Says cantos study of acz885 drug for cardiovascular disease has reached the defined number of events, on track for mid-2017 readout

* Says baf312 filing planned in us h1 2018 in relapsing ms, labeling of population studied a review issue Source text for Eikon: Further company coverage: (Reporting by John Miller)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below